Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.72 |
| ▸ | EED | O75530 | 3/20 | 0.67 |
| ▸ | RBBP4 | Q09028 | 3/20 | 0.67 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.67 |
| ▸ | RBBP7 | Q16576 | 3/20 | 0.67 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.53 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18800336 | 0.95 | EZH2 (0.70) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL18800367 | 0.90 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684276 | 0.90 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL21418329 | 0.88 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10254789 | 0.86 | EZH2 (0.76) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10257026 | 0.86 | EZH2 (0.74) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL14739809 | 0.86 | EZH2 (0.74) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10257356 | 0.86 | EZH2 (0.74) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL18800451 | 0.85 | EZH2 (0.74) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10266382 | 0.85 | EZH2 (0.70) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106659765-B | Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer | 德玛医药 | 2021-08-13 | — | — | CN | disclosed |
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3294284-A1 | COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER | Delmar Pharmaceuticals, Inc. (CA) | 2018-03-21 | — | — | EP | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9637472-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | disclosed |
| WO-2016183331-A1 | COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER | DELMAR PHARMACEUTICALS, INC. (CA) | 2016-11-17 | — | — | WO | disclosed |
| WO-2015154064-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2015-10-08 | — | — | WO | disclosed |
| EP-2681216-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EED 2585/4885RBBP4 2047/4885 |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EED 2585/4885RBBP4 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.